EP Patent

EP3648744A1 — Novel pharmaceutical composition

Assigned to Novartis AG · Expires 2020-05-13 · 6y expired

What this patent protects

Dispersible tablets comprising as active ingredient N- {3- [5- (2-Amino-4-pyrimidinyl) -2- (1,1-dimethylethyl) -1,3-thiazol-4- yl] -2-fluorophenyl} -2,6-difluorobenzenesulfonamide, a methanesulfonate salt, processes for their preparation and methods of use.

USPTO Abstract

Dispersible tablets comprising as active ingredient N- {3- [5- (2-Amino-4-pyrimidinyl) -2- (1,1-dimethylethyl) -1,3-thiazol-4- yl] -2-fluorophenyl} -2,6-difluorobenzenesulfonamide, a methanesulfonate salt, processes for their preparation and methods of use.

Drugs covered by this patent

Patent Metadata

Patent number
EP3648744A1
Jurisdiction
EP
Classification
—
Expires
2020-05-13
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.